First-of-Its-Kind Testing Device Allows For Rapid Detection of Bacteria That Identify Risk for Preterm Birth
|
By LabMedica International staff writers Posted on 14 Oct 2021 |

A newly-developed cost-effective device can rapidly and accurately detect changes in vaginal bacteria and corresponding immune responses in pregnant women, which are associated with increased risk of preterm birth.
The first-of-its-kind testing device developed by researchers at the March of Dimes Prematurity Research Center at Imperial College London (London, UK) may help advance diagnosis and treatment of preterm birth by facilitating faster clinical decision-making and helping improve targeted treatment strategies during pregnancy.
Preterm birth remains a major cause of death worldwide in children under age five. One of the many factors that contribute to a woman's risk of preterm birth is changes during pregnancy to the type and amounts of microbes in the lower reproductive tract, referred to as the vaginal microbiome. In some women, certain bacteria from the microbiome can cause inflammation leading to an increased risk of preterm birth. The new testing device called direct-on-swab metabolic profiling by Desorption Electrospray Ionization Mass Spectrometry (DESI-MS), rapidly analyzes chemicals in a clinical swab to simultaneously determine the type of bacteria in the vagina, and corresponding immune or inflammatory response to the bacteria.
The two-minute test was found to be just as effective as 'gold standard' chemical profiling tests (e.g. Liquid Chromatography-Mass Spectrometry assays) that require detailed sample preparation and extraction making them more time consuming (up to eight hours per assay), costly and difficult to introduce into routine bedside testing. The ability to monitor the vaginal microbiome and inflammation throughout pregnancy with DESI-MS could help identify women at risk of preterm birth sooner, potentially allowing obstetricians to monitor these women more closely and start preventative treatments earlier and in a more targeted way than currently possible.
The researchers tested the direct-on-swab DESI-MS device by analyzing more than 1,000 samples collected from two independent groups of pregnant women (about 400 women in total) in the UK. The data found that women who had changing and diverse vaginal microbiomes (those that contained many different bacteria or had bacteria that changed during pregnancy) had higher rates of preterm birth and were more likely to have increased inflammation. The test also detected inflammation caused by some treatments received during pregnancy (e.g. a stitch put into the cervix for 'cervical cerclage' treatment). This inflammation was most frequently observed in women subsequently experiencing preterm birth.
The device may have broader application to other areas of women's health where the vaginal microbiome has been implicated, including bacterial vaginosis, HIV and HPV infection, cervical dysplasia, IVF failure and miscarriage. The researchers now plan to register the technology and seek regulatory approval for its use in the UK and Europe and, eventually, in North America. They also are planning development of a miniature version of the test that can be used more widely in clinics and would allow for bedside testing.
"We've known for some time that the vaginal microbiome can contribute to the risk of preterm birth, but now we have developed a device which in just a few minutes can report both the microbiome composition and inflammatory status of a sample collected during pregnancy," said Dr. David MacIntyre, Reader in Reproductive Systems Medicine, Institute of Reproductive and Developmental Biology Department of Metabolism, Digestion and Reproduction at Imperial College London. "This is the first rapid testing device of its kind and could be readily transferred to use in a clinical setting. This information could be used by doctors and patients to monitor risk of preterm birth but also to help optimize treatments, such as more selective use of antibiotics."
Related Links:
Imperial College London
Latest Molecular Diagnostics News
- RNA Profiling Uncovers Therapeutic Targets in Solid Tumors
- Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
- New AI Tool Improves Detection of Genetic Causes in Rare Disorders
- Adaptive PCR Platform Improves Consistency in Small-Batch NGS Workflows
- Portable Test Uses CRISPR to Rapidly Identify STIs and Resistance Markers
- New Molecular Test Boosts Accuracy of Bile Duct Cancer Diagnosis
- First IVDR‑Certified IGH Clonality Assay Supports Diagnosis of B-Cell Malignancies
- Plasma ctDNA Testing Predicts Breast Cancer Recurrence After Neoadjuvant Therapy
- New Respiratory Panel Expands Pathogen Detection to 25 Targets
- Nasal Swab May Reveal Early Signs of Alzheimer’s Disease
- Blood Biomarker Predicts Cognitive Outcomes After Cardiac Arrest
- Liquid Biopsy Enables Faster Diagnosis of Childhood Cancer in Africa
- Blood Test Helps Guide Treatment in Older Women with Breast Cancer
- Rapid Host-Response Test Distinguishes Bacterial and Viral Infections in Minutes
- Liquid Biopsy Method Pinpoints Disease Source From a Single Drop of Blood
- Study Reveals Widespread Errors in Gene Variant Naming
Channels
Clinical Chemistry
view channel
AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
Diagnosing the cause of age-related cognitive symptoms remains challenging because clinical presentations of neurodegenerative diseases often overlap, and multiple pathologies can co-occur... Read more
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read more
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more








